May 5, 2023
EL MONTE, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023. First Quarter 2023 Results: Total Revenue of $66.2 million Core Revenue1 grew 150% year-over-year to $62.7 million GAAP loss of $15.3 million, or $0.52 per share Non-GAAP loss of $6.5 million, or $0
Go to Source
Author: